Mild and moderate preterm birth

NEW YORK, August 16 (Praxis Press). Preterm birth is defined as birth before 37 gestational weeks. Although infants born at 32 through 36 weeks are more common than very preterm infants (those born before 32 weeks), most studies have focused on very preterm infants because of their high risk of mortality and serious morbidity. In a new study, Kramer and colleagues examined the contribution of mild (birth between 34 and 36 weeks) and moderate (birth between 32 and 33 weeks) preterm birth to infan

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

NEW YORK, August 16 (Praxis Press). Preterm birth is defined as birth before 37 gestational weeks. Although infants born at 32 through 36 weeks are more common than very preterm infants (those born before 32 weeks), most studies have focused on very preterm infants because of their high risk of mortality and serious morbidity. In a new study, Kramer and colleagues examined the contribution of mild (birth between 34 and 36 weeks) and moderate (birth between 32 and 33 weeks) preterm birth to infant mortality in the US and Canada using birth cohort data for singleton infants born between 1985 and 1994. Compared with infants born at term, the relative risk of death from all causes was 6.6 in the US and 15.2 in Canada among moderate preterm infants. Among mild preterm infants, the corresponding relative risks were 2.9 and 4.5. There is no clear reason why infant mortality was ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform